ZBH · NYQ · Healthcare
Zimmer Biomet Holdings, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 76.17
Market price
USD 95.36
Implied upside
-20.1%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 8.7bn | USD 9.2bn | USD 9.8bn | USD 10.3bn | USD 10.9bn | +5.9% |
| EBIT | USD 1.6bn | USD 1.7bn | USD 1.8bn | USD 1.9bn | USD 2.0bn | +5.9% |
| NOPAT | USD 1.4bn | USD 1.5bn | USD 1.5bn | USD 1.6bn | USD 1.7bn | +5.9% |
| Add depreciation & amortisation | USD 1.1bn | USD 1.2bn | USD 1.3bn | USD 1.4bn | USD 1.4bn | +5.9% |
| Less capital expenditure | USD -1.1bn | USD -1.2bn | USD -1.3bn | USD -1.4bn | USD -1.4bn | +5.9% |
| Less increase in working capital | USD -422.9m | USD -447.7m | USD -473.9m | USD -501.6m | USD -531.0m | +5.9% |
| Free cashflow to firm | USD 949.6m | USD 1.0bn | USD 1.1bn | USD 1.1bn | USD 1.2bn | +5.9% |
| Discount factor | 0.9654 | 0.8996 | 0.8384 | 0.7813 | 0.7281 | - |
| Present value | USD 916.7m | USD 904.3m | USD 892.1m | USD 880.0m | USD 868.1m | -1.4% |
| Present Value Of The Forecast | USD 4.5bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.646 | Reported 0.471, pulled toward 1.0 (Blume) |
| Cost of equity | 8.55% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 18.2bn | 70.8% of capital |
| Total debt | USD 7.5bn | 29.2% of capital, book value as a proxy |
| Tax rate | 13.9% | Effective, capped at statutory |
| WACC | 7.31% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
80% of EV
- Forecast FCFF, final year
- USD 1.2bn
- Capex at depreciation, working capital in reinvestment
- USD 1.7bn
- Less reinvestment at g/ROIC (34.2% of NOPAT)
- USD -589.6m
- Capitalised
- USD 1.1bn
- ROIC (WACC floor)
- 7.3%
- Terminal value, undiscounted
- USD 24.2bn
- Terminal value, discounted
- USD 17.6bn
- Enterprise value
- USD 22.1bn
- Less net debt
- USD 6.9bn
- Equity value
- USD 15.1bn
Exit at 10.3x EBITDA
85% of EV
- Terminal value, undiscounted
- USD 35.2bn
- Terminal value, discounted
- USD 25.7bn
- Enterprise value
- USD 30.1bn
- Less net debt
- USD 6.9bn
- Equity value
- USD 23.2bn
Spread between methods: 42%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 5.31% | 128.41 | 133.57 | 140.36 | 149.86 | 164.33 |
| 6.31% | 94.18 | 94.74 | 95.31 | 95.89 | 96.49 |
| 7.31% | 75.31 | 75.74 | 76.17 | 76.60 | 77.03 |
| 8.31% | 61.08 | 61.45 | 61.81 | 62.18 | 62.54 |
| 9.31% | 49.97 | 50.28 | 50.59 | 50.91 | 51.22 |
Outlined: this model. Green text: above today's price of 95.36. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 5.9% | 11.3% | +5.4pp |
| EBIT margin | 18.3% | 21.2% | +2.9pp |
| Discount rate | 7.3% | 6.3% | -1.0pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.